Joanna Jońska‐Gmyrek

The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease

Beata Kotowicz, Małgorzata Fuksiewicz, Joanna Jońska‐Gmyrek et al. · Tumor Biology · 2015 · 50 citations · Full text

Medicine, Gynecology, Oncology +16

HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk

Agnieszka Żółciak‐Siwińska, Michał Bijok, Joanna Jońska‐Gmyrek et al. · Gynecologic Oncology · 2013 · 49 citations

Medicine, Oncology, Radiation Oncology +14

HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy – a phase III study

Agnieszka Żółciak‐Siwińska, N. Piotrkowicz, Joanna Jońska‐Gmyrek et al. · Radiotherapy and Oncology · 2013 · 36 citations

Medicine, Oncology, Radiation Oncology +14

Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients

Joanna Jońska‐Gmyrek, Leszek Gmyrek, Agnieszka Żółciak‐Siwińska et al. · Cancer Management and Research · 2018 · 36 citations · Full text

Medicine, Hematology, Oncology +14

Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

Beata Kotowicz, Małgorzata Fuksiewicz, Joanna Jońska‐Gmyrek et al. · PLoS ONE · 2017 · 27 citations · Full text

Medicine, Gynecology, Oncology +15